Chardan Capital Maintains Buy on SAB Biotherapeutics, Maintains $12 Price Target

Benzinga · 2d ago
Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and maintains $12 price target.